TY - JOUR
T1 - Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study
AU - Tabor, David E
AU - Fernandes, Fiona
AU - Langedijk, Annefleur C
AU - Wilkins, Deidre
AU - Lebbink, Robert Jan
AU - Tovchigrechko, Andrey
AU - Ruzin, Alexey
AU - Kragten-Tabatabaie, Leyla
AU - Jin, Hong
AU - Esser, Mark T
AU - Bont, Louis J
AU - Abram, Michael E
AU - Hennus, Marije
N1 - Funding Information:
D. E. Tabor, F. Fernandes, D. Wilkins, A. Tovchigrechko, A. Ruzin, H. Jin, M. T. Esser, and M. E. Abram are employees of AstraZeneca and own stock. L. J. Bont, affiliated with the University Medical Centre Utrecht (UMCU) and founding chairman of the ReSViNET Foundation, has not received personal fees or other personal benefits. UMCU has received funding from Abbvie, AstraZeneca, Janssen, The Bill and Melinda Gates Foundation, Nutricia (Danone), and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding from Julius Clinical for participating in the INFORM-RSV study sponsored by AstraZeneca. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017. UMCU received minor funding for consultation and invited lectures by AbbVie, AstraZeneca, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, and Janssen.
Funding Information:
The INFORM-RSV study received funding from AstraZeneca, Sanofi Pasteur, and Julius Clinical.
Publisher Copyright:
© 2020 Tabor et al.
PY - 2021/1
Y1 - 2021/1
N2 - Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among infants and young children, resulting in annual epidemics worldwide. INFORM-RSV is a multiyear clinical study designed to describe the global molecular epidemiology of RSV in children under 5 years of age by monitoring temporal and geographical evolution of current circulating RSV strains, F protein antigenic sites, and their relationships with clinical features of RSV disease. During the pilot season (2017-2018), 410 RSV G-F gene sequences were obtained from 476 RSV-positive nasal samples collected from 8 countries (United Kingdom, Spain, The Netherlands, Finland, Japan, Brazil, South Africa, and Australia). RSV B (all BA9 genotype) predominated over RSV A (all ON1 genotype) globally (69.0% versus 31.0%) and in all countries except South Africa. Geographic clustering patterns highlighted wide transmission and continued evolution with viral spread. Most RSV strains were from infants of <1 year of age (81.2%), males (56.3%), and patients hospitalized for >24 h (70.5%), with no differences in subtype distribution. Compared to 2013 reference sequences, variations at F protein antigenic sites were observed for both RSV A and B strains, with high-frequency polymorphisms at antigenic site Ø (I206M/Q209R) and site V (L172Q/S173L/K191R) in RSV B strains. The INFORM-RSV 2017-2018 pilot season establishes an important molecular baseline of RSV strain distribution and sequence variability with which to track the emergence of new strains and provide an early warning system of neutralization escape variants that may impact transmission or the effectiveness of vaccines and MAbs under development.
AB - Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among infants and young children, resulting in annual epidemics worldwide. INFORM-RSV is a multiyear clinical study designed to describe the global molecular epidemiology of RSV in children under 5 years of age by monitoring temporal and geographical evolution of current circulating RSV strains, F protein antigenic sites, and their relationships with clinical features of RSV disease. During the pilot season (2017-2018), 410 RSV G-F gene sequences were obtained from 476 RSV-positive nasal samples collected from 8 countries (United Kingdom, Spain, The Netherlands, Finland, Japan, Brazil, South Africa, and Australia). RSV B (all BA9 genotype) predominated over RSV A (all ON1 genotype) globally (69.0% versus 31.0%) and in all countries except South Africa. Geographic clustering patterns highlighted wide transmission and continued evolution with viral spread. Most RSV strains were from infants of <1 year of age (81.2%), males (56.3%), and patients hospitalized for >24 h (70.5%), with no differences in subtype distribution. Compared to 2013 reference sequences, variations at F protein antigenic sites were observed for both RSV A and B strains, with high-frequency polymorphisms at antigenic site Ø (I206M/Q209R) and site V (L172Q/S173L/K191R) in RSV B strains. The INFORM-RSV 2017-2018 pilot season establishes an important molecular baseline of RSV strain distribution and sequence variability with which to track the emergence of new strains and provide an early warning system of neutralization escape variants that may impact transmission or the effectiveness of vaccines and MAbs under development.
KW - Evolution
KW - Genetic variation
KW - Molecular epidemiology
KW - Resistance
KW - Respiratory syncytial virus
KW - Surveillance
UR - https://www.scopus.com/pages/publications/85098621149
U2 - 10.1128/JCM.01828-20
DO - 10.1128/JCM.01828-20
M3 - Article
C2 - 33087438
SN - 0095-1137
VL - 59
SP - 1
EP - 13
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
IS - 1
M1 - e01828-20
ER -